stavudine + lamivudine + indinavir

The combination of **stavudine, lamivudine, and indinavir** is an oral, triple antiretroviral regimen used in the management of HIV-1 infection. Stavudine and lamivudine are both nucleoside reverse transcriptase inhibitors (NRTIs), while indinavir is a protease inhibitor. Stavudine inhibits HIV-1 reverse transcriptase by acting as a thymidine analog, leading to premature DNA chain termination after incorporation into viral DNA[4][5]. Lamivudine is a cytosine analog that also terminates viral DNA synthesis by inhibition of reverse transcriptase after phosphorylation to its active triphosphate form[2][5]. Indinavir inhibits the HIV-1 protease enzyme, preventing the cleavage of viral polyproteins, resulting in the production of immature, non-infectious virus particles. Clinical studies have shown the triple combination significantly reduces HIV viral load and increases CD4 cell counts, with greater efficacy and durability compared to dual regimens[1][6]. The regimen may be associated with specific toxicities, such as lactic acidosis, hepatomegaly, peripheral neuropathy (stavudine), and nephrolithiasis (indinavir)[5].

Other names

stavudine + lamivudine + indinavir sulfate